Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study

被引：9

作者：

Luebbert, Michael ^{[1
]}

Rueter, Bjorn ^{[1
]}

Claus, Rainer

Schmid, Mathias ^{[2
]}

Germing, Ulrich ^{[3
]}

Eimeracher, Hartmut ^{[4
]}

Ganser, Arnold ^{[5
]}

Platzbecker, Uwe ^{[6
]}

Galm, Oliver ^{[7
]}

Brugger, Wolfram ^{[8
]}

Heil, Gerhard ^{[9
]}

Wijermans, Pierre W. ^{[10
]}

Pfeifer, Dietmar ^{[1
]}

Schmoor, Claudia ^{[11
]}

Doehner, Hartmut ^{[2
]}

机构：

[1] Univ Hosp, Freiburg, Germany

[2] Univ Hosp, Ulm, Germany

[3] Univ Hosp, Dusseldorf, Germany

[4] Catholic Hosp, Hagen, Germany

[5] Univ Hosp, Hannover, Germany

[6] Univ Hosp, Dresden, Germany

[7] Univ Hosp, Aachen, Germany

[8] Hospital, Villigen Schwenningen, Germany

[9] Hospital, Ludenscheid, Germany

[10] Leyenburg Hosp, The Hague, Netherlands

[11] Univ Hosp, Ctr Clin Trials, Freiburg, Germany

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.300.300

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

300

引用

页码：95A / 95A

页数：1

共 50 条

[41] Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Kienle, Dirk L.
Dietrich, Daniel
Ribi, Karin
Wicki, Andreas
Quagliata, Luca
Winterhalder, Ralph C.
Koeberle, Dieter
Horber, Daniel
Bastian, Sara
Kueng, Marc
Saletti, Piercarlo
Helbling, Daniel
Baertschi, Daniela
Lugli, Alessandro
Bernhard, Juerg
Andrieu, Christiane
von Moos, Roger
JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (02) : 304 - 310
[42] DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy
Grishina, Olga
Schmoor, Claudia
Doehner, Konstanze
Hackanson, Bjoern
Lubrich, Beate
May, Annette M.
Cieslik, Caroline
Mueller, Michael J.
Luebbert, Michael
BMC CANCER, 2015, 15
[43] High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study
Necchi, A.
Mariani, L.
Di Nicola, M.
Lo Vullo, S.
Nicolai, N.
Giannatempo, P.
Raggi, D.
Fare, E.
Magni, M.
Piva, L.
Matteucci, P.
Catanzaro, M.
Biasoni, D.
Torelli, T.
Stagni, S.
Bengala, C.
Barone, C.
Schiavetto, I.
Siena, S.
Carlo-Stella, C.
Pizzocaro, G.
Salvioni, R.
Gianni, A. M.
ANNALS OF ONCOLOGY, 2015, 26 (01) : 167 - 172
[44] Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.
Heidel, F
Cortes, J
Ruecker, F
Kaufmann, M
Aulitzky, W
Letvak, L
Kindler, T
Huber, C
Dohner, H
Kantarjian, H
Fischer, T
BLOOD, 2005, 106 (11) : 527A - 527A
[45] Anti-PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
Wang, Jing
Li, Siqi
Jiang, Hao
Chang, Ying-Jun
Zhao, Xiao-Su
Jia, Jin-Song
Zhu, Xiao-Lu
Gong, Li-Zhong
Liu, Xiao-Hong
Yu, Wen-Jing
Huang, Xiao-Jun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Yokoyama, T.
Yoshioka, H.
Fujimoto, D.
Demura, Y.
Hirano, K.
Kawai, T.
Kagami, R.
Ishida, T.
Tomii, K.
Akai, M.
Hirabayashi, M.
Nishimura, T.
Nakahara, Y.
Kim, Y. H.
Yoshimura, K.
Hirai, T.
ANNALS OF ONCOLOGY, 2019, 30
[47] Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment
Maertens, Johan
Luebbert, Michael
Fiedler, Walter
Fouillard, Loic
Haaland, Alf
Brandwein, Joseph M.
Lepretre, Stephane
Reman, Oumedaly
Turlure, Pascal
Bug, Gesine
Mueller-Tidow, Carsten
Kraemer, Alwin
Voss, Florian
Taube, Tillmann
Fritsch, Holger
Doehner, Hartmut
BLOOD, 2012, 120 (21)
[48] LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS.
Pautier, Patricia
Floquet, Anne
Cupissol, Didier
Lacas, Benjamin
Bompas, Emmanuelle
Chevreau, Christine
Selle, Frederic
Weber, Beatrice E.
Guillemet, Cecile
Penel, Nicolas
Duffaud, Florence
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[49] Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
Smolej, Lukas
Brychtova, Yvona
Cmunt, Eduard
Doubek, Michael
Spacek, Martin
Belada, David
Simkovic, Martin
Stejskal, Lukas
Zygulova, Irena
Urbanova, Renata
Brejcha, Martin
Zuchnicka, Jana
Mocikova, Heidi
Kozak, Tomas
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 769 - 778
[50] Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment
Acker, Fabian
Aguinarte, Lukas
Althoff, Friederike
Heinzen, Sophie
Rost, Maximilian
Wild, Peter
Reiser, Lena
Manz, Martin
Meyer, Frauke
Stratmann, Jan
Sebastian, Martin
CLINICAL LUNG CANCER, 2022, 23 (07) : E473 - E477

← 1 2 3 4 5 →